Anavex Life Sciences (AVXL) Annual Balance Sheets

Annual · GAAP · USD millions
Access AVXL quarterly Balance Sheets →
The balance sheet data below highlights changes in Anavex Life Sciences's financial position over recent quarters.
Annual Report, GAAP in USD millions
ITEM
(Sep 30 2025)
(Sep 30 2024) (Sep 30 2023) (Sep 30 2022) (Sep 30 2021)
Assets
Cash & cash equivalent102.58
Cash & Short-term Investments102.00
Income Taxes Receivable, Current NO0.81
Prepaid Expense And Other Assets Current0.43
Total Current Assets103.82
Other Assets, Noncurrent0.00
Total Assets103.82
Liabilities
Accounts Payable, Current AC4.25
Accrued Liabilities, Current AC3.89
Other Liabilities, Current0.00
Total Current Liabilities8.14
Total Long-term Debt0.00
Deferred Rent Credit DE0.81
Other liabilities, Noncurrent8.14
Total Liabilities8.95
Stockholders' Equity
Common Stock Value0.09
Additional Paid In Capital Common Stock477.23
Retained Earnings / Accumulated Deficit-382.45
Other Equity0.00
Common Stockholder's Equity94.87
Total Stockholder's Equity94.87
Liabilities & Stockholder's Equity103.82
4 historic quarters locked

Sign in to unlock the full Anavex Life Sciences balance sheet history.

About Anavex Life Sciences Corp Annual Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-K filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 10-K (Period: 20250930)
  • Filed with the SEC: November 25, 2025
  • Source: e7052_10-k.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001731122-25-001596

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.

Get the full CSIMarket dataset: Subscribe API License